A new case study published in Cureus by Saami Khalifian, MD; Alec D. McCarthy, MD; and Steven Yoelin, MD, examines the efficacy and safety of an injectable therapy for treating neck wrinkles and skin laxity. This therapy combines hyperdiluted calcium hydroxylapatite (CaHA), platelet-rich plasma (PRP), and hyaluronidase.
Two patients with moderate neck wrinkles and skin laxity received the treatment and were evaluated several months later.
The study found that a single treatment with the combined therapy improved skin texture and laxity.
The inclusion of PRP and hyaluronidase aimed to enhance the regenerative effects of CaHA. PRP is rich in growth factors that stimulate collagen production and regeneration, while hyaluronidase breaks down hyaluronic acid, promoting better diffusion and even product dispersion.
The findings from these cases provide preliminary evidence supporting the safety and efficacy of this innovative combination therapy for addressing neck wrinkles and laxity.
According to the researchers, this is the first documented instance of using CaHA in conjunction with hyaluronidase and PRP for skin priming.
Further investigations are needed to explore the application of this treatment for other anatomical regions and to clarify the role of each injected component.
Read complete findings at Cureus
More from The Blog
FBI Issues Warning on Fraudulent Semaglutide Compounding
The FBI has issued a major warning (Alert I-022825-PSA, Feb 28, 2025) about fraudulent compounding practices involving semaglutide, the active ingredient in Ozempic and Wegovy. This alert is critical for medspa owners, weight loss clinics, and pharmacies—especially...
How To Reset Your Instagram Algorithm: A Fresh Start For Your Feed
When Scrolling Takes a Turn What is the saying - "it's all fun and games until someone gets hurt?" Okay, maybe hurt is extreme, but if you are like me and while doom scrolling you come across a post - and no I won't name names - that is so odd, disturbing, crazy,...
Compounding Pharmacies Fight Back: Why Semaglutide Access Matters
Last December, the FDA announced "shortage" of tirzepatide, last month about Eli Lilly suing Medspa, and just last week, we saw the FDA announce that compounding pharmacies must stop the production and sale of semaglutide. Now, compounding pharmacies are taking legal...
Texas Botox Regulation Under Scrutiny – What Medspa Owners Everywhere Need to Know
In a recent investigative report by KXAN News, significant concerns have been raised about the oversight of Botox and similar injection procedures (e.g. Filler, IV Therapy) in Texas. The findings revealed alarming gaps in regulation that allow almost anyone to become...
